ROS -mediated anticancer response of potent copper(II) drug entities derived from S, O and N, N chelating donor scaffold: Single X-ray crystal diffraction and spectroscopic studies

化学 单斜晶系 结晶学 细胞毒性 三斜晶系 单晶 螯合作用 氧化还原 晶体结构 立体化学 体外 无机化学 生物化学 有机化学
作者
Shariq Yousuf,Farukh Arjmand,Sartaj Tabassum
出处
期刊:Journal of Molecular Structure [Elsevier BV]
卷期号:1262: 132989-132989 被引量:3
标识
DOI:10.1016/j.molstruc.2022.132989
摘要

• The structure of complexes 1 and 2 were thoroughly characterized. • The complexes 1 and 2 were synthesized with an idea of attaining a quick biologically Cu(II)/Cu(I) redox cycle. • The high in vitro cytotoxicity exhibited by five coordinated Cu(II) complex. • Mode of binding of 1 and 2 towards ct-DNA was studied. New Cu(II) anticancer drug entities derived from S, O, and N, N donor chelating scaffolds were synthesized and thoroughly characterized by various spectroscopic and single X-ray diffraction studies. The single X-ray crystal structure of 1 and 2 revealed a monoclinic and triclinic crystal system with space group C 2 / c and P -1, respectively. The biomolecular interaction studies of 1 and 2 with ct-DNA were carried out by employing a battery of biophysical techniques, viz., absorption, emission, circular dichroic, and electrochemical (CV) and corroborative results of these experiments demonstrated avid electrostatic binding via surface groove. The synthesized Cu(II) complexes showed high efficacy as ROS generators involving Cu(II)/Cu(I) redox-active pair as evidenced by cleavage assay in the presence of radical scavengers. The ROS generation in the presence of copper-based complexes is considered one of the most favorable cell death mechanisms for the inhibition of cancers. In vitro anticancer activity of 1 and 2 was, therefore, evaluated against a panel of five human cancer cell lines, namely MCF-7, MDA-MB-231, Hop-62, AW1356, and SiHa, and results of cytotoxicity demonstrated good anticancer response against all tested cancerous strains with GI 50 value <10 µM, except by 1 against MDA-MB-231, Hop-62 and AW1356 cell lines. Interestingly, 2 has displayed considerable cytotoxicity against MCF-7, Hop-62, and SiHa cancer cell lines even better than that of standard drug adriamycin. Furthermore, computational DFT studies validated the high binding efficacy and significant cytotoxicity of complex 2, which could be attributed to high positive charge density over the Cu(II) center. ROS induced DNA damage resulted Cell Death.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
5秒前
urologywang完成签到 ,获得积分10
7秒前
小公牛完成签到 ,获得积分10
8秒前
双手外科结完成签到,获得积分10
12秒前
13秒前
RFlord发布了新的文献求助10
20秒前
李健的小迷弟应助Lumi采纳,获得30
22秒前
29秒前
海英完成签到,获得积分10
40秒前
量子星尘发布了新的文献求助10
43秒前
量子星尘发布了新的文献求助30
1分钟前
1分钟前
小点完成签到 ,获得积分10
1分钟前
ChatGPT发布了新的文献求助10
1分钟前
Lumi发布了新的文献求助30
1分钟前
量子星尘发布了新的文献求助10
1分钟前
蓝豆子完成签到 ,获得积分10
1分钟前
Superman完成签到 ,获得积分10
1分钟前
alan完成签到 ,获得积分0
1分钟前
jiangjiang完成签到,获得积分10
1分钟前
小山己几完成签到,获得积分10
1分钟前
科研通AI5应助科研通管家采纳,获得10
1分钟前
科研通AI5应助科研通管家采纳,获得10
1分钟前
领导范儿应助科研通管家采纳,获得10
1分钟前
leaolf应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
科研通AI6应助科研通管家采纳,获得10
1分钟前
1分钟前
211fjfj完成签到 ,获得积分10
1分钟前
追梦完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助30
1分钟前
ChatGPT发布了新的文献求助10
1分钟前
大轩完成签到 ,获得积分10
1分钟前
1分钟前
梦XING完成签到 ,获得积分10
2分钟前
背书强完成签到 ,获得积分10
2分钟前
安琪琪完成签到 ,获得积分10
2分钟前
manmanzhong完成签到 ,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
The Social Work Ethics Casebook(2nd,Frederic G. R) 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
AASHTO LRFD Bridge Design Specifications (10th Edition) with 2025 Errata 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5128435
求助须知:如何正确求助?哪些是违规求助? 4331130
关于积分的说明 13494178
捐赠科研通 4167056
什么是DOI,文献DOI怎么找? 2284336
邀请新用户注册赠送积分活动 1285334
关于科研通互助平台的介绍 1225882